Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2012. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMR), and connected persons, specifically regarding an increase in their ordinary shareholdings.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial figure disclosed is the transaction price of 1481.43 pence per Ordinary share.
Material Changes
There are no material changes to the company's financial position or operations reported in this document. The filing details a specific transaction where directors and connected persons increased their shareholdings through the re-investment of dividends paid on January 5, 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, outlook, risk factors, or contingencies. It is strictly a regulatory disclosure of share transactions in accordance with Disclosure and Transparency Rules 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Type: Increase in share interests via dividend re-investment.
- Transaction Price: 1481.43 pence per Ordinary share.
- Key Participants: Sir Andrew Witty (559 shares), Lady Caroline Witty (1542 shares), Dr D Pulman (323 shares), Mrs C R Pulman (65 shares), and Mr I W Whyte (62 shares).
- Notification Date: January 6, 2012.
- Dividend Date: January 5, 2012.